Current status of high-intensity focused ultrasound for prostate cancer: technology, clinical outcomes, and future.
Based on a review of recently published articles, we evaluated the current status of high-intensity focused ultrasound (HIFU) as a primary treatment option for localized prostate cancer and as a salvage therapy when radiation has failed. With mid- and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 90%, and an excellent morbidity profile, primary HIFU appears to be a valid alternative to active surveillance protocols in low-risk patients and standard therapies in patients with life expectancies of 10 or fewer years. Moreover, HIFU has a considerable potential for local-only recurrence after radiation failure. HIFU is a recent technology, and many improvements will undoubtedly expand its future indications and use for the management of prostate cancer.
Murat
François-Joseph L
FJ
Urology and Transplantation Department, Edouard Herriot Hospital, 5 Place d'Arsonval, 69347 Lyon Cedex 03, France. gfj-murat@club-internet.fr
Gelet
Albert
A
D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000209:etiology / Q000628:therapy; D011471:Prostatic Neoplasms / Q000628:therapy*; D016896:Treatment Outcome; D014464:Ultrasonic Therapy / Q000009:adverse effects / Q000379:methods* / Q000639:trends*; D036761:Ultrasound, High-Intensity Focused, Transrectal